I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Hepatitis B

What's new

Sign up or login to unlock the full suite of MEDICALLY features

Nov 18 / Roche and Genentech
Efficacy and safety of xalnesiran in combination with the checkpoint inhibitor PD-L1 LNA in virologically suppressed participants with chronic hepatitis B: results from the Piranga phase 2, randomized, controlled, adaptive, open-label platform study
This poster reports on the primary and secondary endpoint results of the combinations of xalnesiran plus PD-L1 LNA in the Piranga phase 2 platform trial for chronic HBV.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 18 / Roche and Genentech
A novel mechanistic viral dynamics modeling (MVDM) framework to characterize and predict the effect of combination therapies in chronic hepatitis B: modeling of the Piranga phase 2, randomized, controlled, adaptive, open-label platform study
Description of a mechanistic model developed to describe the data from Piganga phase 2 platform and understand the effect of each compound on the time course of the different biomarkers. Utilization of the model to simulate different treatment combination strategies.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 15 / Roche and Genentech
Outcomes of nucleos(t)ide analogue discontinuation following finite xalnesiran-based therapy in chronic hepatitis B: 48 week follow-up results from Piranga, a phase 2, randomized, controlled, adaptive, open-label platform study
This poster reports the NA discontinuation events, and the efficacy and safety outcomes of participants in the 4 xalnesiran-based arms from the Piranga phase 2 study.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 15 / Roche and Genentech
Pharmacokinetic/pharmacodynamic modelling of RG6084 effects on hepatitis B surface antigen and alanine transaminase to inform Phase 2 dosing regimen selection
Description of the PK/PD models that were developed using the phase 1 data together with simulations of expected effect for different dose levels supporting the phase 2 dose rational.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 7 / Roche and Genentech
Upcoming Congress
Access to Roche and Genentech's latest medical information
View related congresses

Ask a question or share feedback